NMN & NR

Updated June 29, 2026

NAD+ (nicotinamide adenine dinucleotide) is the central molecule in cellular energy metabolism, serving as the electron carrier in glycolysis, the citric acid cycle, and the mitochondrial electron transport chain. It also powers the sirtuin family of longevity-associated proteins that regulate gene expression, stress resistance, and mitochondrial biogenesis. The problem is that tissue NAD+ levels decline by roughly 50 percent between young adulthood and age 50, and continue falling. That decline tracks closely with reduced mitochondrial function, slower DNA repair, and impaired resilience under metabolic stress.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most studied precursors capable of raising cellular NAD+. Both are forms of vitamin B3 that take distinct entry routes into the NAD+ biosynthesis pathway. NR enters cells via specific nucleoside transporters and is phosphorylated to NMN by NRK enzymes, which then converts to NAD+. NMN is one step further along — the direct precursor — and reaches tissues via a specific small-intestinal transporter identified in recent years. Head-to-head human trials show broadly similar blood NAD+ increases at comparable doses, suggesting the choice between them comes down to individual response, cost, and formulation preference.

Human trials have consistently confirmed that oral NR and NMN raise NAD+ levels in blood and skeletal muscle. The increases are dose-dependent and appear within two to four weeks at standard doses. The clearest benefit signals in controlled studies are in skeletal muscle NAD+ replenishment, improved insulin sensitivity markers in older adults, and reduced inflammatory markers. Some trials in postmenopausal women show measurable cardiovascular improvements. Cognitive and energy benefits are widely reported by users, and animal data strongly supports them, while controlled human trials for cognitive endpoints are still maturing.

Dosing conventions have converged around 250 to 500 mg per day for both compounds. Higher doses up to 1,000 mg have been used in trials without safety concerns, but the benefit above 500 mg appears to plateau in most people. Morning dosing is preferred because the NAMPT enzyme responsible for a key synthesis step follows a circadian rhythm — dosing with breakfast aligns with its natural peak. Sublingual NMN formulations claim improved absorption by bypassing first-pass gut metabolism, and early data supports higher plasma NMN with sublingual delivery, though the long-term NAD+ outcome difference remains modest.

Both compounds are well tolerated. NR occasionally causes mild flushing at higher doses, similar to niacin but milder. NMN is typically flush-free. The strongest case for supplementation is in people over forty whose natural NAD+ production has meaningfully declined, used alongside exercise and quality sleep — both of which independently boost NAD+ through their own pathways. This is general information, not medical advice.